On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experienceSudipta Chakraborty, Ashutosh Dash, K.V. Vimalnath et al.|Journal of Radioanalytical and Nuclear Chemistry|2014Cited by 51
Prospects of medium specific activity <sup>177</sup>Lu in targeted therapy of prostate cancer using <sup>177</sup>Lu‐labeled PSMA inhibitorSudipta Chakraborty, Ashutosh Dash, Rubel Chakravarty et al.|Journal of Labelled Compounds and Radiopharmaceuticals|2016Cited by 27
Aspects of yield and specific activity of (n,γ) produced 177Lu used in targeted radionuclide therapyK.V. Vimalnath, Ashutosh Dash, Priyalata Shetty et al.|Journal of Radioanalytical and Nuclear Chemistry|2014Cited by 19
Reactor production of 32P for medical applications: an assessment of 32S(n,p)32P and 31P(n,γ)32P methodsK.V. Vimalnath, Ashutosh Dash, A. Rajeswari et al.|Journal of Radioanalytical and Nuclear Chemistry|2014Cited by 19
<sup>64</sup> CuCl <sub>2</sub> produced by direct neutron activation route as a cost-effective probe for cancer imaging: the journey has begunRubel Chakravarty, Ashutosh Dash, Sudipta Chakraborty et al.|RSC Advances|2015Cited by 17